Melagatran

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Melagatran
DrugBank Accession Number
DB13616
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 429.5126
Monoisotopic: 429.237604505
Chemical Formula
C22H31N5O4
Synonyms
  • Melagatran
  • Melagatrán
  • Mélagatran
  • Melagatranum

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Melagatran.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Melagatran.
AcemetacinThe risk or severity of bleeding and hemorrhage can be increased when Melagatran is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Melagatran.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Melagatran.
Food Interactions
  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
B01AE04 — Melagatran
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid amides / Alpha amino acids / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Amino acids / Azetidines / Monocarboxylic acids and derivatives / Azacyclic compounds / Dialkylamines
show 7 more
Substituents
Alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-dipeptide / Amidine / Amine / Amino acid / Amino acid or derivatives / Aromatic heteromonocyclic compound / Azacycle
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
carboxamidine, dicarboxylic acid monoamide, secondary amino compound, non-proteinogenic alpha-amino acid, azetidines (CHEBI:43966)
Affected organisms
Not Available

Chemical Identifiers

UNII
2A9QP32MD4
CAS number
159776-70-2
InChI Key
DKWNMCUOEDMMIN-PKOBYXMFSA-N
InChI
InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1
IUPAC Name
2-{[(1R)-2-[(2S)-2-{[(4-carbamimidoylphenyl)methyl]carbamoyl}azetidin-1-yl]-1-cyclohexyl-2-oxoethyl]amino}acetic acid
SMILES
[H][C@]1(CCN1C(=O)[C@H](NCC(O)=O)C1CCCCC1)C(=O)NCC1=CC=C(C=C1)C(N)=N

References

General References
Not Available
KEGG Drug
D07143
ChemSpider
159822
BindingDB
29388
ChEBI
43966
ChEMBL
CHEMBL266349
ZINC
ZINC000003809827
PDBe Ligand
MEL
Wikipedia
Ximelagatran
PDB Entries
1k1p / 1k22 / 4bah

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedPreventionThromboembolism1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.117 mg/mLALOGPS
logP-0.51ALOGPS
logP-1.3Chemaxon
logS-3.6ALOGPS
pKa (Strongest Acidic)3.2Chemaxon
pKa (Strongest Basic)11.48Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count5Chemaxon
Polar Surface Area148.61 Å2Chemaxon
Rotatable Bond Count9Chemaxon
Refractivity125.7 m3·mol-1Chemaxon
Polarizability46.84 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0620900000-bc62b1ec838e40c75c33
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-0621900000-82a53c258c91a6775b6c
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-4897800000-3133aaa37a0aedf98c95
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-003r-2669400000-e1d3e24c4bdb4527c842
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0159-2951000000-1d42494648aa2fe9e826
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-005c-6930100000-98af8c95ed759a39bacb
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-197.35146
predicted
DeepCCS 1.0 (2019)
[M+H]+199.74704
predicted
DeepCCS 1.0 (2019)
[M+Na]+206.31262
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:45 / Updated at February 21, 2021 18:54